An AbbVie medicinal chemistry team had identified a promising series of trisubstituted cyclopropanes during a drug discovery campaign focused on developing CFTR C2 correctors for the treatment of cystic fibrosis. This evidence concerns the gene CFTR and cystic fibrosis.